Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: A single-centre experience

Annals of Hematology

Volumn 88, Issue 7, 2009, Pages 681-685

  Frossard, Valérie ^a   Ketterer, Nicolas ^a   Rosselet, Anne ^a   Meier, Pascal ^a   Cairoli, Anne ^a   Duchosal, Michel A ^a   Kovacsovics, Tibor ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

AL amyloidosis; Autologous stem cell transplantation; Chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ACUTE KIDNEY FAILURE; ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY DISEASES; MALE; MELPHALAN; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 67349124830     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0652-z     Document Type: Article

References (23)

1. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1997) A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207. doi: 10.1056/NEJM199704243361702
2. Comenzo RL, Gertz MA (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99:4276-4282. doi: 10.1182/ blood.V99.12.4276
3. Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC (2007) Long-term outcome of patients with al amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 110:3561-3563. doi: 10.1182/blood-2007-07-099481
4. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG (2004) High-dose melphalan and autologous stem-cell transplantation in patients with al amyloidosis: An 8-year study. Ann Intern Med 140:85-93
5. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, Litzow MR (2002) Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 113:549-555. doi: 10.1016/S0002-9343(02)01208-1
6. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA (2004) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood 103:3960-3963. doi: 10.1182/blood-2003-12-4192
7. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, Berk JL, Dember LM, Falk RH, Skinner M (2004) Improvement in quality of life of patients with al amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 104:1888-1893. doi: 10.1182/blood-2004-01-0089
8. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'Hara C, Arkin CF, Wright DG, Skinner M (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of al (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91:3662-3670
9. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP (2007) High-dose melphalan versus melphalan plus dexamethasone for al amyloidosis. N Engl J Med 357:1083-1093. doi: 10.1056/NEJMoa070484
10. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: Results of a phase ii trial. Br J Haematol 139:224-233. doi: 10.1111/j.1365-2141.2007.06783.x
11. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (al): A consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 april 2004. Am J Hematol 79:319-328. doi: 10.1002/ajh.20381
12. Perz JB, Rahemtulla A, Giles C, Szydlo RM, Davis J, Gopaul D, Gillmore J, Mathias CJ, Hawkins PN, Apperley JF (2006) Long-term outcome of high-dose melphalan and autologous stem cell transplantation for al amyloidosis. Bone Marrow Transplant 37:937-943. doi: 10.1038/ sj.bmt.1705354
13. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS (2004) Prognostication of survival using cardiac troponins and n-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881-1887. doi: 10.1182/blood-2004-01-0390
14. Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G (2006) Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (al) amyloidosis. Haematologica 91:1635-1643
15. Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM (2003) Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for al amyloidosis. Kidney Int 63:1868-1873. doi: 10.1046/j.1523-1755.2003.00936.x
16. Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M (2001) Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 134:746-753
17. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of al amyloidosis: Results of a prospective randomized trial. Bone Marrow Transplant 33:381-388. doi: 10.1038/sj.bmt.1704346
18. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107:3378-3383. doi: 10.1182/blood-2005-07-2922
19. Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, Cha SS, Gertz MA (2007) Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2:440-444. doi: 10.2215/CJN.02450706
20. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2008) Efficacy of bortezomib in systemic al amyloidosis with relapsed/ refractory clonal disease. Haematologica 93:295-298. doi: 10.3324/ haematol.11627
21. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic al amyloidosis. Blood 109:457-464. doi: 10.1182/blood-2006-07-035352
22. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-470. doi: 10.1182/blood-2006-07-032987
23. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC (2007) Lenalidomide and dexamethasone in the treatment of al amyloidosis: Results of a phase 2 trial. Blood 109:492-496. doi: 10.1182/blood-2006-07-030544